

10 May 2016 EMA/251741/2016 Human Medicines Evaluation Division

# Targeted consultation on development of new medicinal products for the treatment of rheumatoid arthritis

## Programme

7 June 2016 European Medicines Agency, London, United Kingdom

Meeting room 2A





## Objectives of the meeting

- To provide interested stakeholders the opportunity to discuss the most up-to-date scientific views relevant to the development of medicinal products in RA with leading experts in this area
- · To provide a forum of discussion on suitable study designs and possible label for new substances

## List of speakers

Jan Mueller-Berghaus Paul-Ehrlich-Institute (PEI), Germany

Rheumatology Immunology Working Party (RIWP)

Committee for Medicinal Products for Human Use (CHMP)

Arantxa Sancho-Lopez Spanish Agency of Medicines and Medical Devices (AEMPS),

Spain

Rheumatology Immunology Working Party (RIWP)

Committee for Medicinal Products for Human Use (CHMP)

**Elisabeth Johanne Rook** Medicines Evaluation Board (CBG-MEB), Netherlands

Rheumatology Immunology Working Party (RIWP)

Enrica Alteri European Medicines Agency (EMA)

Richard Vesely European Medicines Agency (EMA)

Andreas Kouroumalis European Medicines Agency (EMA)

# **Programme details**

## 9:00 Registration

Registration and badge collection at the reception on the ground floor.

The meeting room 2A is on the second floor.

10:00	Welcome and opening
	Enrica Alteri
	Richard Vesely
10:15	Introduction
	Jan Mueller-Berghaus
20′	The development of the guideline for development of new medicinal products for the treatment of rheumatoid arthritis
	Jan Mueller-Berghaus
	Elisabeth Rook
10:40	Session 1: From clinical trials to regulatory approval
20′	Defining and selecting populations to be studied in rheumatoid arthritis Extrapolation of clinical benefit between different populations in rheumatoid arthritis
	Jan Mueller-Berghaus
60′	Discussion
12:00-13:00	Discussion  Lunch break
	Lunch break
12:00-13:00	Lunch break  Session 2: Endpoints in clinical trials
12:00-13:00 13:00	Lunch break
12:00-13:00 13:00	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response
12:00-13:00 13:00	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response Feasibility and need to demonstrate prevention of structural damage
12:00-13:00 13:00 20'	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response Feasibility and need to demonstrate prevention of structural damage Arantxa Sancho-Lopez
12:00-13:00 13:00 20' 60' 14:20-14:40	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response Feasibility and need to demonstrate prevention of structural damage Arantxa Sancho-Lopez  Discussion  Coffee break
12:00-13:00 13:00 20' 60' 14:20-14:40 14:40	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response Feasibility and need to demonstrate prevention of structural damage Arantxa Sancho-Lopez  Discussion  Coffee break  Session 3: Clinical trial designs
12:00-13:00 13:00 20' 60' 14:20-14:40	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response Feasibility and need to demonstrate prevention of structural damage Arantxa Sancho-Lopez  Discussion  Coffee break  Session 3: Clinical trial designs  Placebo vs. active control: when and for how long
12:00-13:00 13:00 20' 60' 14:20-14:40 14:40	Lunch break  Session 2: Endpoints in clinical trials  Disease activity criteria vs. relative response Feasibility and need to demonstrate prevention of structural damage Arantxa Sancho-Lopez  Discussion  Coffee break  Session 3: Clinical trial designs

## 60' Discussion

## 16:00 Conclusions and next steps

Jan Mueller-Berghaus Richard Vesely

#### **Travel and Accommodation**

Participants must possess valid travel documents and, where relevant, a visa for entry into the United Kingdom. Should you require an official letter of invitation, please contact <a href="mailto:RIWPsecretariat@ema.europa.eu">RIWPsecretariat@ema.europa.eu</a>


#### **Recording and Photography**

The Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency as enshrined in the Treaty on the European Union. The conference will be recorded. By attending these events you consent to any photographing, recording, broadcast and publication of presentations on the EMA website.

#### Contact

Should you have any questions, please contact Monica Simeoni or Andreas Kouroumalis via RIWPsecretariat@ema.europa.eu

#### Directions to European Medicines Agency and map of the area



#### By Docklands Light Railway (DLR)

Both venues are a short walk from Canary Wharf or Heron Quays station on the DLR. Services run from Bank, Tower Gateway, Lewisham, Stratford, King George V and Beckton.

## By Underground

The nearest stop for both venues is Canary Wharf station on the Jubilee Line.

#### **By Bus**

Canary Wharf is serviced by local bus numbers D3, D7, D8, 135 and 277.

#### **River services**

River services run between Embankment, London Bridge and Canary Wharf throughout the day. Canary Wharf pier is roughly a 15-minute walk from the European Medicines Agency.

#### **From London City Airport**

Take a taxi to Canary Wharf, or catch the DLR to Westferry station then change to the DLR to Canary Wharf.

#### **Useful links**

http://www.tfl.gov.uk/

National Rail

**Gatwick Express** 

**Heathorw Express** 

**Stansted Express** 

Eurostar

**Heathrow airport** 

**Gatwick airport** 

**London City** 

**London Stansted** 

Hillgate travel